AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31378318
Drug: Moxifloxacin 400-mg
RxNorm normalized name: moxifloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin 400-mg oral dose
Trial: 19856512
Drug: Chloroquine regimen
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloroquine regimen group A (1200 mg total over 3 days: 600 mg on day 1, 300 mg on days 2 and 3)
Trial: 19856512
Drug: Chloroquine regimen
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloroquine regimen group B (1500 mg total over 3 days: 750 mg on day 1, 375 mg on days 2 and 3)
Trial: 16480348
Drug: Anaesthetist-administered propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anaesthetist-administered propofol sedation
Trial: 15333431
Drug: EDLA (extended-duration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EDLA (extended-duration local anesthetic) at concentrations of 6.25, 12.5, and 25 mg/mL
Trial: 15333431
Drug: Aqueous bupivacaine
RxNorm normalized name: Pen-Aqueous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous bupivacaine (5.0 mg/mL)
Trial: 11140434
Drug: Micronised fluticasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronised fluticasone propionate 0.1 mg, twice daily for 4 days
Trial: 11140434
Drug: Micronised fluticasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronised fluticasone propionate 1 mg, twice daily for 4 days
Trial: 11140434
Drug: Micronised fluticasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronised fluticasone propionate 10 mg, twice daily for 4 days
Trial: 11140434
Drug: Placebo, twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, twice daily for 4 days
Trial: 9062598
Drug: Intraperitoneal bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal bupivacaine (15 ml of 0.5% bupivacaine injected twice)
Trial: 9062598
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (15 ml of 0.9% saline solution injected twice)
Trial: 3481331
Drug: Ofloxacin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin (200 or 400mg twice daily)
Trial: 3481331
Drug: Doxycycline (100mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline (100mg twice daily)
Trial: 28784001
Drug: Maintenance tocolysis
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance tocolysis with tablet nifedipine for 12 days or up to 34 weeks of gestation.
Trial: 18234355
Drug: Paroxetine or
RxNorm normalized name: paroxetine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine or citalopram treatment for 1 year
Trial: 12859470
Drug: Topical anaesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anaesthesia using an atomiser
Trial: 10375948
Drug: Active sarcoidosis
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active sarcoidosis treated with steroids
Trial: 7076102
Drug: Nitrofurantoin macrocrystals
RxNorm normalized name: Nitrofurantoin Macrocrystals
DrugBank: Nitrofurantoin (DB00698)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitrofurantoin macrocrystals (100 mg every 12 hours for two days)
Trial: 7076102
Drug: Trimethoprim/sulfamethoxazole (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim/sulfamethoxazole (160 mg and 800 mg respectively every 12 hours for two days)
Trial: 27595687
Drug: CCTA in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCTA in combination with CTP
Trial: 17669143
Drug: Propiverine 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propiverine 20 mg
Trial: 15498087
Drug: Pramlintide 60
RxNorm normalized name: PRAMLINTIDE 600MCG/ML SOLN INJ 5ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramlintide 60 microg three times daily (TID)
Trial: 15498087
Drug: Pramlintide 60
RxNorm normalized name: PRAMLINTIDE 600MCG/ML SOLN INJ 5ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramlintide 60 microg four times daily (QID)
Trial: 9572539
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium (DS) 0.1% solution, 1 drop four times daily for 14 days
Trial: 9572539
Drug: Ketorolac tromethamine
RxNorm normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketorolac tromethamine (KT) 0.5% solution, 1 drop four times daily for 14 days
Trial: 8113776
Drug: Day Hospital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day Hospital (DH) rehabilitation (27 hours of weekday treatment weekly)
Trial: 8113776
Drug: Inpatient (INP)
RxNorm normalized name: Impatiens irvingii whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inpatient (INP) rehabilitation (48 hours of scheduled treatment weekly)
Trial: 2455331
Drug: Carbachol (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbachol (0.25 mg s.c.)
Trial: 2455331
Drug: Oral Carbachol
RxNorm normalized name: Carbachol
DrugBank: Carbamoylcholine (DB00411)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Carbachol (6 or 12 mg/day for 2 weeks)
Trial: 19483180
Drug: Bupropion SR
RxNorm normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupropion SR 300 mg/day
Trial: 11403727
Drug: Bupropion SR
RxNorm normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupropion SR 150 mg/day
Trial: 16325470
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose quinapril (10 mg/day)
Trial: 11127501
Drug: Inhaling an
RxNorm normalized name: Aldex AN
DrugBank: Doxylamine (DB00366)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaling an anti-cholinergic drug
Trial: 8861087
Drug: Tibolone (Livial,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibolone (Livial, 2.5 mg daily)
Trial: 8861087
Drug: Conjugated estrogens
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated estrogens (Premarin, 0.625 mg daily) + Medrogestone (Colpron, 2 x 5 mg daily for 12 days each month)
Trial: 1298968
Drug: Sulodexide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulodexide (100 mg/die)
Trial: 6723531
Drug: High-dosage recombinant
RxNorm normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dosage recombinant alpha 2 interferon (rIFN-alpha 2) administered as 50 X 10(6) E/m2 as 30-minute infusion on 5 consecutive days four-weekly
Trial: 6723531
Drug: High-dosage recombinant
RxNorm normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dosage recombinant alpha 2 interferon (rIFN-alpha 2) administered as 20 X 10(6) E/m2 subcutaneously thrice weekly
Trial: 27189282
Drug: COX‐2 inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COX‐2 inhibitor (COX‐2i)
Trial: 22307926
Drug: Intravenous hyoscine
RxNorm normalized name: HYOSCINE HYDROBROMIDE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous hyoscine butylbromide
Trial: 22307926
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of paracetamol + hyoscine butylbromide
Trial: 17852629
Drug: 2.5% testosterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5% testosterone gel
Trial: 16342345
Drug: DDDR pacing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DDDR pacing and antiarrhythmic drugs
Trial: 8907133
Drug: Levosimendan 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan 0.25 mg
Trial: 8907133
Drug: Levosimendan 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan 0.5 mg
Trial: 8907133
Drug: Levosimendan 4
RxNorm normalized name: Levosimendán
DrugBank: Levosimendan (DB00922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan 4 mg
Trial: 356707
Drug: High-dose pentazocine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose pentazocine (0.9 mg/kg)
Trial: 28174052
Drug: Expedited transfer
RxNorm normalized name: SET,TRANSFER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Expedited transfer to a cardiac arrest centre (CAC) for goal-directed therapy including access to immediate reperfusion
Trial: 26194186
Drug: Preoperative chemoradiation
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative chemoradiation plus perioperative ECF chemotherapy
Trial: 23585314
Drug: Nomogram 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nomogram 1 (bolus of 80 U/Kg/h and initial infusion rate of 17 U/Kg/h)
Trial: 23585314
Drug: Nomogram 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nomogram 2 (bolus of 60 U/Kg, maximum of 4000 U, and initial infusion rate of 12 U/Kg/h, maximum of 900 U/h)
Trial: 18376260
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg lansoprazole once per day (group A)
Trial: 18376260
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg lansoprazole twice per day (group B)
Trial: 12667306
Drug: Chemotherapy combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy combined with Isorel biotherapy (29 patients)
Trial: 12667306
Drug: Only chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Only chemotherapy (21 patients)
Trial: 10894870
Drug: Thalidomide 800
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Thalidomide 800 mg (escalated to 1,200 mg)
Trial: 10461824
Drug: Thalidomide 200
RxNorm normalized name: thalidomide 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thalidomide 200 mg
Trial: 1465754
Drug: Inhaled bradykinin
RxNorm normalized name: Bradykinin
DrugBank: Bradykinin (DB12126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled bradykinin (8 mg/ml)
Trial: 31801567
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (1.5 g), Thiamine (100 mg), and Hydrocortisone (50 mg) given every 6 h for up to 16 doses
Trial: 24462479
Drug: 12-session 12-step
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 12-session 12-step facilitation therapy (TSF)
Trial: 23171020
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral azithromycin (10 mg/kg/d) plus allopurinol (10 mg/kg/d) for two months
Trial: 23171020
Drug: Intramuscular Glucantime
RxNorm normalized name: Glucantim
DrugBank: Meglumine antimoniate (DB13732)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular Glucantime (20 mg/kg of antimony daily for 20 days)
Trial: 15565575
Drug: DCC method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DCC method for scoring estrogen receptor (ER)
Trial: 7497685
Drug: Articulating spacer
RxNorm normalized name: follicle stimulating hormone / luteinizing hormone Injection [Menopur]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Articulating spacer with antibiotic-impregnated cement
Trial: 1827368
Drug: Topical tetracycline
RxNorm normalized name: TETRACYCLINE HYDROCHLORIDE 30 mg in 1 mL TOPICAL SPRAY [Tetracyte Topical Tetracycline Hydrochloride]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tetracycline (Topicycline)
Trial: 1827368
Drug: 5% benzoyl-peroxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% benzoyl-peroxide gel
Trial: 1827368
Drug: Oral oxytetracycline
RxNorm normalized name: Oxytetracycline
DrugBank: Oxytetracycline (DB00595)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral oxytetracycline (250 mg twice daily)
Trial: 7040493
Drug: Bumetanide (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bumetanide (1 mg, increased to a maximum of 10 mg daily)
Trial: 7040493
Drug: Furosemide (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide (40 mg, increased to a maximum of 400 mg daily)
Trial: 31805932
Drug: Treatment costs
RxNorm normalized name: costus root oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment costs due to complications
Trial: 27744016
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (Group A)
Trial: 15040805
Drug: conservative standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: conservative standard therapy
Trial: 11847411
Drug: NaCl 0.9%
RxNorm normalized name: DEXTROSE 5%/NACL 0.9% INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaCl 0.9% solution
Trial: 31809325
Drug: Intravenous open
RxNorm normalized name: BOTTLE OPENER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous open label placebo
Trial: 20433733
Drug: Mechanical traction
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanical traction with extension-oriented treatment approach
Trial: 20433733
Drug: Extension-oriented treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extension-oriented treatment approach without mechanical traction
Trial: 16554199
Drug: Initial endodontic
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial endodontic treatment
Trial: 7892081
Drug: Combined schedule
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined schedule of inactivated polio vaccine followed by two doses of live attenuated oral polio vaccine
Trial: 7892081
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated oral polio vaccine (three doses)
Trial: 3258660
Drug: Conjugated polyribosyl
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated polyribosyl ribitol phosphate (PRP) vaccine
Trial: 3258660
Drug: Unconjugated polyribosyl
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unconjugated polyribosyl ribitol phosphate (PRP) vaccine
Trial: 30980421
Drug: Misoprostol/phenytoin gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol/phenytoin gel treatment on two wounds
Trial: 17032160
Drug: Manual Assisted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual Assisted Cognitive Treatment (MACT)
Trial: 11066029
Drug: Mucolytic medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mucolytic medication
Trial: 9337828
Drug: Exhalation at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exhalation at an expiratory flow rate of 250 ml/min
Trial: 9337828
Drug: Exhalation at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exhalation at an expiratory flow rate of 1100 ml/min
Trial: 1426295
Drug: Digital rectal
RxNorm normalized name: BD Thermometer Digital Rectal (obsolete)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital rectal examination (DRE)
Trial: 30626496
Drug: Massage therapy
RxNorm normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Massage therapy plus usual care
Trial: 29178728
Drug: Higher abrasivity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher abrasivity daily-use whitening dentifrice (1,100 ppm fluoride as sodium fluoride; RDA137)
Trial: 24014214
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate 100 mg/day for 5 days plus uFSH 37.5 IU/day
Trial: 18751491
Drug: Surgical hand
RxNorm normalized name: ALCOHOL 75 mL in 100 mL Topical GEL [Wash-Free Surgical Hand Disinfectant Gel II]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical hand antisepsis solutions (specific solutions not mentioned)
Trial: 12865477
Drug: Testosterone undecanoate
RxNorm normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone undecanoate (80 mg twice daily)
Trial: 8694165
Drug: Syntocinon (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Syntocinon (1 ml, 10 units)
Trial: 8694165
Drug: Saline (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (1 ml, placebo)
Trial: 1905592
Drug: Sustained-release diltiazem
RxNorm normalized name: diltiazem
DrugBank: Diltiazem (DB00343)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sustained-release diltiazem 180 mg b.i.d.
Trial: 6410280
Drug: Drug counseling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug counseling alone (DC)
Trial: 31868694
Drug: Horse-riding therapy
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Horse-riding therapy (H-RT)
Trial: 31868694
Drug: Rhythm and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhythm and music-based therapy (R-MT)
Trial: 29311155
Drug: Sitagliptin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin therapy
Trial: 27095003
Drug: Human α1-antitrypsin
RxNorm normalized name: herpesvirus 1, human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human α1-antitrypsin (A1AT) 240 mg/kg
Trial: 19786415
Drug: Escitalopram during
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram during intravenous interferon-alpha therapy
Trial: 19786415
Drug: Methylphenidate during
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate during intravenous interferon-alpha therapy
Trial: 19786415
Drug: Escitalopram and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram and methylphenidate together during subcutaneous interferon therapy
Trial: 19786415
Drug: Alternate agent
RxNorm normalized name: Alternaria alternata
DrugBank: Alternaria alternata (DB10424)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternate agent alone during subcutaneous interferon therapy
Trial: 17514589
Drug: Hypoglycemia (induced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypoglycemia (induced by insulin 0.1 IU/kg intravenously)
Trial: 17514589
Drug: Apomorphine (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apomorphine (0.75 mg subcutaneously)
Trial: 17514589
Drug: Hypoglycemia (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypoglycemia (after previous treatment with apomorphine)
Trial: 19348328
Drug: Curosurf administration
RxNorm normalized name: Curosurf
DrugBank: Poractant alfa (DB09113)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Curosurf administration
Trial: 16957969
Drug: Intradermal (ID)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal (ID) injection of 99mTc-sulfur colloid
Trial: 16957969
Drug: Intraparenchymal (IP)
RxNorm normalized name: IP-2018
DrugBank: IP-2018 (DB19049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraparenchymal (IP) injection of 99mTc-sulfur colloid
Trial: 16957969
Drug: Subareolar (SA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subareolar (SA) injection of 99mTc-sulfur colloid
Trial: 10831163
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) treatment (0.125 IU/kg/wk for 4 weeks, then 0.25 IU/kg/wk for 6 months)
Trial: 6368753
Drug: Rectal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rectal administration of diazepam 20 mg
Trial: 6368753
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of diazepam 20 mg
Trial: 25427598
Drug: Thiopental (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopental (4 mg/kg IV)
Trial: 25427598
Drug: Ketamine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (2 mg/kg IV)
Trial: 24227734
Drug: Responses to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Responses to body effectors (e.g., hands, feet, limbs) in lateral occipitotemporal cortex (LOTC) and parietal cortex.
Trial: 21848497
Drug: Low-dose transdermal
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose transdermal estradiol (E2) gel (0.9 g/day, containing E2 0.54 mg/day)
Trial: 19214559
Drug: Treatment-related factors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-related factors
Trial: 11869171
Drug: Glibenclamide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glibenclamide (10 mg day-1)
Trial: 11869171
Drug: Acarbose (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarbose (300 mg day-1)
Trial: 2738909
Drug: Alpha-gliadin antibodies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-gliadin antibodies (AGA) of subclasses IgG1 and IgG3 in coeliac patients
Trial: 29278929
Drug: Tolterodine 2
RxNorm normalized name: tolterodine 2 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolterodine 2 mg orally (PO)
Trial: 29278929
Drug: Gabapentin 600
RxNorm normalized name: gabapentin 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin 600 mg PO